Home
About
Overview
Sharing Data
ORCID
Help
History (30)
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations.
Development of a Novel Screening Strategy Designed to Discover a New Class of HIV Drugs.
Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes.
HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
Improving Viral Protease Inhibitors to Counter Drug Resistance.
See All 30 Pages
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Improving Viral Protease Inhibitors to Counter Drug Resistance.
Kurt Yilmaz N, Swanstrom R, Schiffer CA. Improving Viral Protease Inhibitors to Counter Drug Resistance. Trends Microbiol. 2016 07; 24(7):547-557.
View in:
PubMed
subject areas
Drug Design
Drug Resistance, Viral
Hepatitis C
HIV Infections
HIV Protease
Humans
Protease Inhibitors
authors with profiles
Celia A Schiffer PhD
Nese Kurt Yilmaz PhD